
## David Lillicrap

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8335002/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Role of von Willebrand factor in venous thromboembolic disease. JVS Vascular Science, 2022, 3, 17-29.	0.4	8
2	Multifaceted pathomolecular mechanism of a <i>VWF</i> large deletion involved in the pathogenesis of severe VWD. Blood Advances, 2022, 6, 1038-1053.	2.5	4
3	Scientific method and the COVID pandemic. Journal of Thrombosis and Haemostasis, 2022, 20, 547-548.	1.9	0
4	Low von Willebrand factor phenotype: the enigma continues. Blood, 2022, 139, 2102-2103.	0.6	1
5	Changes and challenges in the new year. Journal of Thrombosis and Haemostasis, 2022, 20, 1-1.	1.9	0
6	Investment in the future of thrombosis and hemostasis science. Journal of Thrombosis and Haemostasis, 2022, 20, 1033-1033.	1.9	0
7	von Willebrand factor propeptide variants lead to impaired storage and ER retention in patientâ€derived endothelial colonyâ€forming cells. Journal of Thrombosis and Haemostasis, 2022, 20, 1599-1609.	1.9	4
8	Application of in-vitro-cultured primary hepatocytes to evaluate species translatability and AAV transduction mechanisms of action. Molecular Therapy - Methods and Clinical Development, 2022, 26, 61-71.	1.8	3
9	The diagnosis of a haemophilia A carrier over 2 decades. Haemophilia, 2021, 27, e133-e136.	1.0	1
10	Assembly of alternative prothrombinase by extracellular histones initiates and disseminates intravascular coagulation. Blood, 2021, 137, 103-114.	0.6	33
11	Factor VIII pharmacokinetics associates with genetic modifiers of VWF and FVIII clearance in an adult hemophilia A population. Journal of Thrombosis and Haemostasis, 2021, 19, 654-663.	1.9	11
12	Multimerin 1 supports platelet function in vivo and binds to specific GPAGPOGPX motifs in fibrillar collagens that enhance platelet adhesion. Journal of Thrombosis and Haemostasis, 2021, 19, 547-561.	1.9	15
13	Evaluating the potential benefits of the extravascular pool of factor IX. Blood Coagulation and Fibrinolysis, 2021, 32, 68-69.	0.5	8
14	A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects. Thrombosis and Haemostasis, 2021, 121, 1326-1336.	1.8	12
15	Changes for 2021. Journal of Thrombosis and Haemostasis, 2021, 19, 1-1.	1.9	0
16	Molecular coevolution of coagulation factor VIII and von Willebrand factor. Blood Advances, 2021, 5, 812-822.	2.5	4
17	Functional Roles of the von Willebrand Factor Propeptide. Hamostaseologie, 2021, 41, 063-068.	0.9	7
18	Hemophilia Gene Therapy: Approaching the First Licensed Product. HemaSphere, 2021, 5, e540.	1.2	40

#	Article	IF	CITATIONS
19	Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID) Tj ETQq1 Trials, 2021, 22, 202.	1 0,78431 0.7	4 rgBT /Over
20	Evidenceâ€based medicine in thrombosis and hemostasis: ISTH to the fore. Journal of Thrombosis and Haemostasis, 2021, 19, 1845-1846.	1.9	0
21	Gene therapy for hemophilia: Current status and laboratory consequences. International Journal of Laboratory Hematology, 2021, 43, 117-123.	0.7	15
22	To clot or not to clot? Ad is the question—Insights on mechanisms related to vaccineâ€induced thrombotic thrombocytopenia. Journal of Thrombosis and Haemostasis, 2021, 19, 2845-2856.	1.9	16
23	Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ, The, 2021, 375, n2400.	3.0	250
24	COVIDâ€19 — Two years in. Journal of Thrombosis and Haemostasis, 2021, 19, 2905-2905.	1.9	0
25	Randomized trials of therapeutic heparin for COVIDâ€19: A metaâ€analysis. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12638.	1.0	39
26	Changes. Journal of Thrombosis and Haemostasis, 2020, 18, 1-1.	1.9	2
27	2020 – Year of COVIDâ€19. Journal of Thrombosis and Haemostasis, 2020, 18, 2081-2081.	1.9	2
28	Endothelial characteristics in healthy endothelial colony forming cells; generating a robust and valid ex vivo model for vascular disease. Journal of Thrombosis and Haemostasis, 2020, 18, 2721-2731.	1.9	18
29	The challenge of genetically unresolved haemophilia A patients: Interest of the combination of whole <i>F8</i> gene sequencing and functional assays. Haemophilia, 2020, 26, 1056-1063.	1.0	11
30	A virtual ISTH Congress. Journal of Thrombosis and Haemostasis, 2020, 18, 1237-1237.	1.9	0
31	von Willebrand Factor Is a Critical Mediator of Deep Vein Thrombosis in a Mouse Model of Diet-Induced Obesity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2860-2874.	1.1	23
32	The end of an extraordinary year. Journal of Thrombosis and Haemostasis, 2020, 18, 3129-3129.	1.9	0
33	Gut dysbiosis modulates the immune response to factor VIII in murine hemophilia A. Blood Advances, 2020, 4, 2644-2655.	2.5	1
34	Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms. Expert Review of Hematology, 2020, 13, 313-321.	1.0	15
35	Hemophilia gene therapy knowledge and perceptions: Results of an international survey. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 644-651.	1.0	14
36	Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round Table. Haemophilia, 2020, 26, 443-449.	1.0	15

#	Article	IF	CITATIONS
37	Disseminated intravascular coagulation in patients with 2019â€nCoV pneumonia. Journal of Thrombosis and Haemostasis, 2020, 18, 786-787.	1.9	264
38	Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcÎ <sup>3</sup> RIIB Receptor. Frontiers in Immunology, 2020, 11, 138.	2.2	6
39	Sedimentation Velocity Analytical Ultracentrifugation of Oxidized Recombinant Full-Length Factor VIII. Frontiers in Immunology, 2020, 11, 150.	2.2	0
40	Advances in knowledge of inhibitor formation in severe haemophilia A. British Journal of Haematology, 2020, 189, 39-53.	1.2	25
41	The highly prevalent deletions in F8 intron 13 found in French mild hemophilia A patients result from both founder effect and recurrent de novo events. Journal of Thrombosis and Haemostasis, 2020, 18, 1087-1093.	1.9	5
42	A sticky proposition: The endothelial glycocalyx and von Willebrand factor. Journal of Thrombosis and Haemostasis, 2020, 18, 781-785.	1.9	13
43	Hemostasis and thrombosis 101—A challenge to energize. Journal of Thrombosis and Haemostasis, 2020, 18, 269-269.	1.9	1
44	COVIDâ€19: 2020 a year in turmoil. Journal of Thrombosis and Haemostasis, 2020, 18, 993.	1.9	4
45	Advances and challenges for hemophilia gene therapy. Human Molecular Genetics, 2019, 28, R95-R101.	1.4	73
46	Innovative Molecular Testing Strategies for Adjunctive Investigations in Hemostasis and Thrombosis. Seminars in Thrombosis and Hemostasis, 2019, 45, 751-756.	1.5	3
47	Genomic momentum for hemostasis and thrombosis. Journal of Thrombosis and Haemostasis, 2019, 17, 1411-1411.	1.9	0
48	Abstract thoughts of hemostasis. Journal of Thrombosis and Haemostasis, 2019, 17, 245-245.	1.9	0
49	Challenges in diagnosis of von Willebrand disease in the presence of combined mutations of different genes. Haemophilia, 2019, 25, e113-e117.	1.0	0
50	The scavenger receptor SCARA5 is an endocytic receptor for von Willebrand factor expressed by littoral cells in the human spleen. Journal of Thrombosis and Haemostasis, 2019, 17, 1384-1396.	1.9	17
51	Shear stress and platelet-induced tensile forces regulate ADAMTS13-localization within the platelet thrombus. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 254-260.	1.0	5
52	Simplify, simplify. Journal of Thrombosis and Haemostasis, 2019, 17, 711-711.	1.9	0
53	Comparative pharmacokinetics of two extended halfâ€life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?. Journal of Thrombosis and Haemostasis, 2019, 17, 1085-1096.	1.9	34
54	The endothelial lectin clearance receptorCLEC4M binds and internalizes factorVIIIin aVWFâ€dependent and independent manner. Journal of Thrombosis and Haemostasis, 2019, 17, 681-694.	1.9	32

#	Article	IF	CITATIONS
55	Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report. HemaSphere, 2019, 3, e286.	1.2	43
56	Fifty years new. Journal of Thrombosis and Haemostasis, 2019, 17, 1-1.	1.9	6
57	Tolerating Factor VIII: Recent Progress. Frontiers in Immunology, 2019, 10, 2991.	2.2	52
58	Dexamethasone promotes durable factor VIII-specific tolerance in hemophilia A mice via thymic mechanisms. Haematologica, 2018, 103, 1403-1413.	1.7	7
59	Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia. Blood, 2018, 131, 2205-2214.	0.6	26
60	The common VWF single nucleotide variants c.2365A>G and c.2385T>C modify VWF biosynthesis and clearance. Blood Advances, 2018, 2, 1585-1594.	2.5	14
61	N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice. Haematologica, 2018, 103, 1925-1936.	1.7	23
62	The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity. Journal of Clinical Investigation, 2018, 128, 4057-4073.	3.9	67
63	The Highly Prevalent Deletions in F8 Intron 13 Found in French Mild Haemophilia a Patients Result of Both Founder Effect and Recurrent De Novo Events. Blood, 2018, 132, 2489-2489.	0.6	0
64	Utility of factor VIII and factor VIII to von Willebrand factor ratio in identifying 277 unselected carriers of hemophilia A. American Journal of Hematology, 2017, 92, E94-E96.	2.0	10
65	Biological considerations of plasma-derived and recombinant factor VIII immunogenicity. Blood, 2017, 129, 3147-3154.	0.6	38
66	Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation. Journal of Visualized Experiments, 2017, , .	0.2	6
67	Thrombolytic Potential of <i>N</i> -Acetylcysteine. Circulation, 2017, 136, 661-663.	1.6	2
68	FIX It in One Go: Enhanced Factor IX Gene Therapy for Hemophilia B. Cell, 2017, 171, 1478-1480.	13.5	7
69	Bispecific Antibody Therapy in Hemophilia. New England Journal of Medicine, 2017, 377, 884-885.	13.9	9
70	Functional characterisation of the type 1 von Willebrand disease candidate VWF gene variants: p.M771I, p.L881R and p.P1413L. Blood Transfusion, 2017, 15, 548-556.	0.3	2
71	Gene Therapy for Coagulation Disorders. Circulation Research, 2016, 118, 1443-1452.	2.0	17
72	Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. Blood, 2016, 127, 2481-2488.	0.6	96

#	Article	IF	CITATIONS
73	Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A. Blood, 2016, 127, 3439-3449.	0.6	27
74	Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice. Cellular Immunology, 2016, 301, 30-39.	1.4	53
75	War and peace: Factor VIII and the adaptive immune response. Cellular Immunology, 2016, 301, 2-7.	1.4	13
76	To clear or to fear: An innate perspective on factor VIII immunity. Cellular Immunology, 2016, 301, 82-89.	1.4	13
77	Differential Glycosylation Between Recombinant Factor VIII Produced in Baby Hamster Kidney and Chinese Hamster Ovary Cells Confers Differences in Immunogenicity in a Humanized Hemophilia Î <sup>4</sup> Mouse Model. Blood, 2016, 128, 326-326.	0.6	1
78	VWF-FVIII Interactions Influence Hemostatic Thrombus Stability in Murine Models of Hemophilia Α and Type 2N VWD. Blood, 2016, 128, 1403-1403.	0.6	0
79	Development of an Optimized rAAV2/6 Human Factor 8 cDNA Vector Cassette for Hemophilia a Gene Therapy. Blood, 2016, 128, 1173-1173.	0.6	1
80	Foreword. European Journal of Haematology, 2015, 95, 1-1.	1.1	0
81	Transgene-host cell interactions mediate significant influences on the production, stability, and function of recombinant canine FVIII. Molecular Therapy - Methods and Clinical Development, 2015, 2, 15033.	1.8	2
82	Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity. Haematologica, 2015, 100, 149-156.	1.7	37
83	Analysis of the role of von Willebrand factor, platelet glycoprotein VI-, and α2β1-mediated collagen binding in thrombus formation. Blood, 2014, 124, 1799-1807.	0.6	26
84	Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response. Blood, 2014, 123, 4045-4053.	0.6	28
85	von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood, 2013, 122, 3735-3740.	0.6	147
86	The future of hemostasis management. Pediatric Blood and Cancer, 2013, 60, S44-7.	0.8	4
87	von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Hematology American Society of Hematology Education Program, 2013, 2013, 254-260.	0.9	35
88	A Novel Cell-Sheet Technology That Achieves Durable Factor VIII Delivery in a Mouse Model of Hemophilia A. PLoS ONE, 2013, 8, e83280.	1.1	31
89	The Endothelial Lectin Receptor CLEC4M Internalizes Factor VIII and Von Willebrand Factor Via a Clathrin-Coated Pit-Dependent Mechanism. Blood, 2013, 122, 1091-1091.	0.6	4
90	Regulation Of Factor VIII Clearance By Mannose-Binding Lectins. Blood, 2013, 122, 2340-2340.	0.6	1

#	Article	IF	CITATIONS
91	The Complete Type I VWD Cohort Of The Zimmerman Program For The Molecular and Clinical Biology Of VWD - Phenotypic Assignment, Mutation Frequency, and Bleeding Assessment. Blood, 2013, 122, 332-332.	0.6	6
92	Platelet-Mediated Mechanical Tensile Force Influences ADAMTS13 Localization and Regulation Of Thrombus Development At The Site Of Platelet Accumulation. Blood, 2013, 122, 454-454.	0.6	0
93	Myeloid-Derived Suppressor Cell (MDSC) Dynamics In FVIII-Exposed Hemophilia A Mice: Novel Therapeutic Implications. Blood, 2013, 122, 3569-3569.	0.6	0
94	Cardiac decellularisation with longâ€ŧerm storage and repopulation with canine peripheral blood progenitor cells. Canadian Journal of Chemical Engineering, 2012, 90, 1457-1464.	0.9	14
95	The World Federation of Hemophilia and research. Haemophilia, 2012, 18, 24-27.	1.0	3
96	Genetic Variability of the CLEC4M Endothelial Lectin Receptor Modulates Binding and Internalization of Von Willebrand Factor and Contributes to Variance in Plasma VWF Levels. Blood, 2012, 120, 16-16.	0.6	3
97	Surgical Injury Alone Does Not Provoke the Development of Factor VIII Inhibitors in Mouse Models of Hemophilia A. Blood, 2012, 120, 627-627.	0.6	5
98	Ten-Year Canadian National Prospective Data On Utilization of Anti-Hemophilic Concentrates: Indications and Trends. Blood, 2012, 120, 1186-1186.	0.6	0
99	Functional Characterization of the Type 1 VWD Candidate VWF Gene Variants: P.M771I, p.L881R, p.P1413L, and p.Q1475X. Blood, 2012, 120, 97-97.	0.6	0
100	Comprehensive In Vitro and In Vivo Characterization of Loss and Gain-of-Function Von Willebrand Factor Collagen Binding Variants Using a Mouse Model System,. Blood, 2011, 118, 3266-3266.	0.6	0
101	Improvements in factor concentrates. Current Opinion in Hematology, 2010, 17, 393-397.	1.2	34
102	Mouse Models of the Common, Recurring Type 1 von Willebrand Disease Mutations Y1584C and R1205H. Blood, 2010, 116, 22-22.	0.6	6
103	A Modified Model of Type 2B von Willebrand Disease: Taking ADAMTS13-Mediated Cleavage out of the Equation. Blood, 2010, 116, 23-23.	0.6	3
104	Investigation of the Role of Copy Number Variation In the Pathogenesis of Type 1 Von Willebrand Disease. Blood, 2010, 116, 2218-2218.	0.6	0
105	Quantitation of Changes in VWF and FVIII Following Elective Orthopedic Surgery in Normal Individuals Blood, 2009, 114, 1296-1296.	0.6	1
106	Genetically-Engineered Endothelial Cells Implanted Into the Omentum of Hemophilia A Dogs Provides Long-Term Circulating FVIII Resulting From Sustained FVIII Expression and Persistent Cell Viability Blood, 2009, 114, 3578-3578.	0.6	13
107	Immune-Modulatory Effects of Mesenchymal Stromal Cell Infusions for the Treatment of Factor VIII Inhibitor in Hemophilia A Blood, 2009, 114, 1299-1299.	0.6	3
108	In Vitro and In Vivo Mouse Models of the Type 1 Von Willebrand Disease Mutations Y1584C and R1205H Blood, 2009, 114, 26-26.	0.6	8

#	Article	IF	CITATIONS
109	Results of a World Wide Survey On the Diagnostic Dilemma Between Type 2B Von Willeband Disease and the PT-VWD Blood, 2009, 114, 4436-4436.	0.6	0
110	Extending half-life in coagulation factors: where do we stand?. Thrombosis Research, 2008, 122, S2-S8.	0.8	28
111	The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood, 2007, 109, 145-154.	0.6	210
112	The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood, 2007, 109, 145-154.	0.6	310
113	Von Willebrand disease—Phenotype versus genotype: Deficiency versus disease. Thrombosis Research, 2007, 120, S11-S16.	0.8	38
114	The Role of Immunomodulation in the Management of Factor VIII Inhibitors. Hematology American Society of Hematology Education Program, 2006, 2006, 421-425.	0.9	14
115	Gene Expression: Overview and Clinical Implications. Vox Sanguinis, 2002, 83, 77-79.	0.7	5
116	The â^'1185 A/G and â^'1051 G/A dimorphisms in the von Willebrand factor gene promoter and risk of myocardial infarction. British Journal of Haematology, 2001, 115, 701-706.	1.2	19
117	Variation at the von Willebrand Factor (vWF) Gene Locus Is Associated With Plasma vWF:Ag Levels: Identification of Three Novel Single Nucleotide Polymorphisms in the vWF Gene Promoter. Blood, 1999, 93, 4277-4283.	0.6	110
118	Androgen effects on factor IX expression:inâ€vitroandinâ€vivostudies in mice. British Journal of Haematology, 1998, 101, 273-279.	1.2	7
119	Severe haemophilia A in a female resulting from two de novo factor VIII mutations. British Journal of Haematology, 1995, 90, 906-909.	1.2	29
120	Rapid genotype analysis in type 2B von Willebrand's disease using a universal heteroduplex generator. British Journal of Haematology, 1995, 89, 152-156.	1.2	13
121	Multiplex analysis of two intragenic microsatellite repeat polymorphisms in the genetic diagnosis of haemophilia A. British Journal of Haematology, 1994, 86, 810-815.	1.2	28
122	Positive Immunoglobulin Gene Rearrangement Study by the Polymerase Chain Reaction in a Colonic Adenocarcinoma. American Journal of Clinical Pathology, 1992, 98, 116-119.	0.4	17
123	Recurring mutations at CpG dinucleotides in the region of the von Willebrand factor gene encoding the glycoprotein Ib binding domain, in patients with type IIB von Willebrand's disease. British Journal of Haematology, 1991, 79, 612-617.	1.2	18
124	A past mutation at Isoleucine397is now a common cause of moderate/mild haemophilia B. British Journal of Haematology, 1990, 75, 212-216.	1.2	34
125	Basic Principles Underlying the Coagulation System. , 0, , 1-7.		1

#	Article	IF	CITATIONS
127	Qualitative Platelet Disorders. , 0, , 83-90.		1
128	Appendices: Normal Ranges. , 0, , 209-213.		0
129	Disseminated Intravascular Coagulation and other Microanjiopathies. , 0, , 91-100.		0
130	Arterial Thrombosis. , 0, , 114-119.		0
131	Anticoagulation. , 0, , 120-129.		0
132	Intensive/Critical Care. , 0, , 158-171.		0
133	Cardiothoracic Surgery. , 0, , 172-181.		0
134	Hepatology. , 0, , 182-189.		1
135	Transfuction. , 0, , 201-208.		0
136	Hemophilia A and B. , 0, , 39-50.		0
137	The Rarer Inherited Coagulation Disorders. , 0, , 62-68.		0
138	Quantitative Platelet Disorders. , 0, , 69-82.		0
139	Appendices: Useful Websites. , 0, , 214-215.		0
140	Laboratory Tests of Hemostasis. , 0, , 8-17.		1
141	Tests of Platelet Function. , 0, , 29-38.		0
142	Longitudinal bleeding assessment in von willebrand disease utilising an interim bleeding score. Journal of Thrombosis and Haemostasis, 0, , .	1.9	5